INS and type 2 diabetes mellitus: Additionally, a pilot randomized controlled study that compared sitagliptin monotherapy and its combination with basal insulin in hospitalized type 2 diabetic patients, demonstrating comparable efficacy and safety profiles for both treatment strategies (29).